Tirzepatide Published Literature Summary
Last Updated: August 2026A source-linked summary of third-party tirzepatide studies across metabolic and related endpoints. The published findings concern the regulated study or marketed products evaluated under the cited conditions.
Study overview
Evidence by study and endpoint
The cited publications report results from specific products, populations, study arms, and observation periods. Results for an approved prescription product cannot be transferred to a differently manufactured or supplied material.
Trial findings are specific to the cited study conditions.
The numerical findings describe the products supplied for the cited trials. They do not establish the identity, purity, safety, efficacy, or equivalence of any material sold by Precision Synthetics Canada.
SURMOUNT-4 randomized-withdrawal design
SURMOUNT-4 compared continued treatment with a switch to placebo after an open-label lead-in. The reported changes apply to that randomized-withdrawal design.
Head-to-head evidence
SURMOUNT-5 compared tirzepatide with semaglutide in adults with obesity or overweight without diabetes, adding direct comparative context to the evidence base.
Beyond body weight
Separate publications report endpoints in sleep apnea, liver disease, and obesity-related HFpEF. Those findings should be interpreted within each study population and protocol.
Pharmacology
Mechanism of action
The cited pharmacology literature describes tirzepatide as a dual GIP- and GLP-1-receptor agonist with greater relative activity at the GIP receptor. This mechanistic summary is not an instruction or a claim about PSC materials.
GLP-1 Receptor Activity
Glucagon-like peptide-1 (GLP-1) agonism predominantly regulates glucose metabolism by enhancing glucose-dependent insulin secretion and suppressing inappropriate glucagon secretion. It slows gastric emptying and operates centrally in the brain to signal satiety and reduce caloric intake.
GIP Receptor Activity
Glucose-dependent insulinotropic polypeptide (GIP) agonism acts synergistically with GLP-1. Modulating the GIP receptor has been shown in pre-clinical and clinical models to enhance insulin sensitivity, improve lipid metabolism, and regulate white adipose tissue function, limiting ectopic fat deposition.
Reported trial data
Clinical data dashboard
These charts reproduce selected reported endpoints. Populations, estimands, durations, comparators, and study arms differ; the original publications control if a summary differs from a source.
Endpoint summary
Research landscape
A concise overview of the main clinical themes represented in tirzepatide's published and regulatory evidence base.
| Research area | Study / setting | Reported signal | Study context |
|---|---|---|---|
| SURMOUNT-1 obesity study | SURMOUNT-1; 72 weeks | Up to 20.9% mean body-weight reduction at 15 mg | Result reported for the randomized study population and specified study arms. |
| Obesity with Type 2 Diabetes | SURMOUNT-2; 72 weeks | Up to 15.7% mean body-weight reduction at 15 mg | Result reported in participants with type 2 diabetes under the trial protocol. |
| Active comparator obesity | SURMOUNT-5; 72 weeks | 20.2% mean reduction with tirzepatide vs 13.7% with semaglutide | Provides direct head-to-head context against a single GLP-1 receptor agonist. |
| Type 2 diabetes | SURPASS-2; 40 weeks | Up to 2.30% mean HbA1c reduction at 15 mg | Active-comparator result from the specified 40-week trial. |
| Obstructive sleep apnea | SURMOUNT-OSA; 52 weeks | Clinically meaningful reductions in apnea-hypopnea events | Supported the first FDA approval of a medication for moderate-to-severe OSA in adults with obesity. |
| MASH / liver fibrosis | SYNERGY-NASH; 52 weeks | High-dose group reported 74% MASH resolution without worsening fibrosis | Phase 2 finding from the specified MASH population and histologic endpoint. |
| HFpEF with obesity | SUMMIT; median follow-up about two years | Lower composite risk of cardiovascular death or worsening heart-failure event vs placebo | Clinical-outcome result from the specified HFpEF population. |
Additional resources
Recent evidence additions
Selected newer resources expand the page beyond the original obesity and diabetes dashboard.
SURMOUNT-5
Head-to-head comparison of tirzepatide versus semaglutide for obesity treatment without diabetes.
Review summary ?SUMMIT HFpEF
Obesity-related heart failure with preserved ejection fraction trial evaluating clinical outcomes and health status.
Review summary ?FDA OSA approval
Regulatory milestone for moderate-to-severe obstructive sleep apnea in adults with obesity.
FDA release ?Study summaries
Review source-specific findings
Each panel identifies its study design, population, duration, comparator, and reported endpoints. Dose values identify trial arms and are not a protocol.
SURMOUNT-1: placebo-controlled trial
Design: 72-week trial evaluating 2,539 adults with BMI ≥30, or ≥27 with comorbidities, without diabetes.
Reported outcomes: The 15 mg study arm had a 20.9% mean body-weight reduction under the trial estimand. Refer to the article for confidence intervals, adverse events, and analysis details.
SURMOUNT-3: lifestyle intervention lead-in
Design: Tirzepatide was evaluated after a 12-week intensive lifestyle intervention, where participants had already lost weight through diet and activity changes.
Outcomes: Adding tirzepatide was associated with an additional 21.1% weight reduction, with total mean reduction from study entry reported at 26.6%.
SURMOUNT-4: randomized-withdrawal study
Design: Participants completed a 36-week open-label lead-in, followed by randomized continuation of tirzepatide or switch to placebo.
Outcomes: Continued tirzepatide maintained and extended weight reduction, while withdrawal was associated with substantial weight regain.
SURPASS-2: active-comparator trial
Design: 40-week direct comparison of tirzepatide 5, 10, and 15 mg against semaglutide 1 mg in type 2 diabetes.
Reported outcomes: The tirzepatide 15 mg study arm had a mean HbA1c change of -2.30%, compared with -1.86% for the semaglutide 1 mg study arm. Refer to the publication for the prespecified comparisons and confidence intervals.
SURMOUNT-2: obesity with type 2 diabetes
Design: 72-week trial in 938 adults with obesity or overweight and type 2 diabetes.
Reported outcomes: The 15 mg study arm had a 15.7% mean body-weight reduction under the study protocol, together with reported glycemic endpoints.
SURPASS-4: cardiovascular risk cohort
Design: Study in participants with type 2 diabetes and increased cardiovascular risk, comparing tirzepatide against titrated insulin glargine.
Reported outcomes: The publication reported greater mean changes in glycemic and body-weight endpoints for the specified tirzepatide study arms than for the titrated insulin-glargine comparator.
SURMOUNT-OSA: obstructive sleep apnea
Reported outcomes: The publication reported changes in apnea-hypopnea index and related endpoints in adults with obesity and moderate-to-severe obstructive sleep apnea.
SYNERGY-NASH: MASH and fibrosis
Outcomes: The high-dose group reported 74% MASH resolution without worsening fibrosis, with a meaningful proportion also showing fibrosis-stage improvement.
SUMMIT: HFpEF with obesity
Outcomes: In adults with obesity and heart failure with preserved ejection fraction, tirzepatide lowered the composite risk of cardiovascular death or worsening heart-failure events compared with placebo and improved health-status measures.
Study methods
Protocol-controlled procedures
The cited trials used investigator-controlled study arms and escalation procedures under clinical supervision. This page does not reproduce those procedures or provide instructions for preparation, administration, amount, frequency, or escalation. Consult the original publication and registered protocol for the complete methodology.
Terminology
Glossary of terms
Incretin Hormones
Metabolic hormones (like GLP-1 and GIP) that are released from the gut into the bloodstream in response to food ingestion, helping to lower blood glucose levels by stimulating insulin release and reducing appetite.
GIP vs. GLP-1
GLP-1 and GIP are incretin hormones involved in glucose-dependent insulin secretion and other metabolic pathways. Their combined contribution should be interpreted from the cited pharmacology and clinical studies.
HFpEF
Heart Failure with Preserved Ejection Fraction. A condition where the heart pumps normally but is too stiff to fill properly. Incretin therapies are actively being researched for cardiovascular outcome improvements in HFpEF patients with obesity.
OSA
Obstructive Sleep Apnea. A sleep-related breathing disorder characterized by repeated episodes of complete or partial airway obstruction.
References & source data
- SURMOUNT-1: Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
- SURMOUNT-2: Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. The Lancet. https://doi.org/10.1016/S0140-6736(23)01200-X
- SURMOUNT-3: Wadden, T. A., et al. (2023). Tirzepatide after intensive lifestyle intervention for adults with overweight or obesity. Nature Medicine. https://doi.org/10.1038/s41591-023-02597-w
- SURMOUNT-4: Aronne, L. J., et al. (2023). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. https://doi.org/10.1001/jama.2023.24945
- SURMOUNT-5: Aronne, L. J., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. The New England Journal of Medicine. ACC study summary
- SURPASS-2: Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2107519
- SURPASS-4: Del Prato, S., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk. The Lancet. https://doi.org/10.1016/S0140-6736(21)02188-7
- SURMOUNT-OSA: Malhotra, A., et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2404881
- SYNERGY-NASH: Loomba, R., et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2401943
- SUMMIT HFpEF: Tirzepatide for heart failure with preserved ejection fraction and obesity. ACC trial summary
- Regulatory milestone: FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. FDA press announcement